Shares jumped to $11.80 in after-hours trading on August 10, reversing a 5.49% regular-session decline, as investors scrambled to position ahead of Fennec Pharmaceuticals' second-quarter 2026 results, due before the market opens on August 11. The company confirmed it would release Q2 figures before the opening bell, with management hosting a conference call at 8:30 a.m. Eastern. The stakes are high for a small-cap biotech whose entire revenue line depends on a single drug.

  • A Blowout Q1 Set the Bar Sky-High. In Q1 2026, Fennec posted $15.1 million in net revenue, a 73% year-over-year surge that topped analyst expectations of $13.84 million.

The company even squeezed out a profit — $0.01 per share — versus a consensus loss of $0.02.

Wall Street now expects Q2 revenue of roughly $16.1 million , meaning investors buying tonight are betting management's expanded sales force kept the trajectory climbing. Any miss would sting hard given the after-hours premium already baked in.

  • One Product Carries All the Weight. Fennec's entire business rests on PEDMARK, an injection approved to reduce hearing loss caused by the chemotherapy drug cisplatin in pediatric cancer patients.

Full-year 2025 net product sales hit $44.6 million, up 50% year-over-year , and clinical studies are now exploring the drug in adolescent, young adult, and adult cancers of the head, neck, and testes. Broadening the patient pool is essential — without it, the addressable market stays narrow.

  • Spending Is Ramping Faster Than Revenue. Selling and marketing expenses ballooned to $11.4 million in Q1, up from $3.2 million a year earlier, driven by the sales-force expansion.

The company turned cash-flow positive — generating $2.4 million from operations — while holding $40.2 million in cash. Investors will want proof on the call that those marketing dollars are converting to prescriptions, not just overhead.

  • Generic Protection Buys Time, Not Forever. A settlement with generic drugmaker Cipla blocks cheaper copycat versions of PEDMARK in the U.S. until September 2033. That gives Fennec roughly seven more years of pricing power. Analysts have lifted their consensus price target to $16 , with an overall Buy rating — implying roughly 35% upside from today's after-hours price. Whether the Q2 print validates that optimism could set the stock's direction for the rest of the year.